Advertisement

© 2010

The Tumor Microenvironment

  • Rebecca G. Bagley
Book

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xviii
  2. Physiological Parameters

    1. Front Matter
      Pages 1-1
    2. Pawel Swietach, Adrian L. Harris, Richard D. Vaughan-Jones
      Pages 23-41
    3. Olga V. Razorenova, Amato J. Giaccia
      Pages 43-58
    4. Weiqin Lu, Peng Huang
      Pages 91-118
  3. Malignant Cells

    1. Front Matter
      Pages 119-119
    2. Toshikazu Ushijima
      Pages 121-132
    3. Mark R. Kelley, Millie M. Georgiadis, Melissa L. Fishel
      Pages 133-168
    4. Mario Federico, Antonio Giordano
      Pages 169-185
    5. Douglas M. Noonan, Giuseppina Pennesi, Adriana Albini
      Pages 213-228
    6. Paloma Bragado, Aparna C. Ranganathan, Julio A. Aguirre-Ghiso
      Pages 229-254
  4. Vasculature And Stroma

    1. Front Matter
      Pages 255-255
    2. Pravin J. Mishra, Debabrata Banerjee
      Pages 275-288
    3. Barbara Garmy-Susini
      Pages 289-309
    4. Koji Matsuo, Chunhua Lu, Mian M. K. Shazad, Robert L. Coleman, Anil K. Sood
      Pages 311-323
    5. Urszula M. Polanska, Kieran T. Mellody, Akira Orimo
      Pages 325-349

About this book

Introduction

The field of cancer biology and developmental therapeutics is continually evolving as new methodologies are developed and new targets are discovered. Although multiple therapeutics directly target the malignant cells these drugs rarely prevent recurrence of disease or the progression of metastasis. The complex biology of tumors presents challenges in designing treatments that will eliminate the malignant cells as well as the supporting network of vasculature and stroma that allows for the comparison of tumors to developing organs in embryos. In addition to blood vessels and malignant cells, tumors consist of fibroblasts, immune and inflammatory cells, and a myriad of proteins that comprise the extracellular matrix. Effective eradication of malignant disease requires therapeutic strategies that factor in targeting the tumor microenvironment. In the past decade, a new class of anticancer drugs has emerged that interferes with tumor angiogenesis; however the clinical benefit from treatment with the first generation antiangiogenic agents added to the standard of care is often modest. Thus, there remains a critical need to understand the tumor microenvironment and to develop anti-cancer therapies that address this aspect of malignant disease. The first edition of The Tumor Microenvironment is intended to give a current perspective on the role of the tumor microenvironment in malignant progression and detail strategies for novel therapies directed towards the cellular matrix. This book explores the many biological and physiological aspects of the tumor as a tissue and includes chapters on the variety of cells that influence tumor growth and spread as well as the cell-associated and soluble proteins that can promote invasion and metastasis. Several chapters describe endothelial cells and pericytes that form tumor vasculature. Insights into the role of progenitor and stem cells are included. The contribution of the supporting stroma is addressed in addition to cell-cell signaling and cell-matrix interactions. Additional chapters describe the influence of infiltrating cells of the immune system on tumor growth. The Tumor Microenvironment is the definitive text detailing cutting edge research by experts in the field and will be a valued resource in the study of this important area of cancer biology for many years to come.

Keywords

Chemokine DNA angiogenesis cancer therapy carcinogenesis carcinoma cell immunotherapy lymphocytes macrophages metastasis methylation research tumor tumor growth

Editors and affiliations

  • Rebecca G. Bagley
    • 1
  1. 1.Genzyme CorporationFraminghamUSA

About the editors

Rebecca Bagley is a senior scientist at Genzyme Corporation and has worked in the biotechnology industry for 20 years with degrees in biology from Wellesley College and Harvard University. Her expertise in drug development spans a wide range of approaches including immunotherapies, gene and protein therapies, and small molecule delivery with publications in journals such as Molecular Cancer Therapeutics, Cancer Research, and Microvascular Research . Her current research focuses on stem cells, tumor vasculature, and target validation.

Bibliographic information

  • Book Title The Tumor Microenvironment
  • Editors Rebecca G. Bagley
  • Series Title Cancer Drug Discovery and Development
  • Series Abbreviated Title Cancer Drug Discovery, Development
  • DOI https://doi.org/10.1007/978-1-4419-6615-5
  • Copyright Information Springer Science+Business Media, LLC 2010
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine Medicine (R0)
  • Hardcover ISBN 978-1-4419-6614-8
  • Softcover ISBN 978-1-4614-2660-8
  • eBook ISBN 978-1-4419-6615-5
  • Edition Number 1
  • Number of Pages XVIII, 770
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Cancer Research
    Pharmacology/Toxicology
  • Buy this book on publisher's site
Industry Sectors
Biomedicine
Pharma
Health & Hospitals
Biotechnology
Oncology & Hematology
Consumer Packaged Goods